Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Aug;28(2):246–251. doi: 10.1128/aac.28.2.246

Selective in vitro and in vivo activities of 5-(2-haloalkyl)pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus.

E De Clercq, B Rosenwirth
PMCID: PMC180227  PMID: 3010841

Abstract

5-(2-Chloroethyl)-2'-deoxyuridine (CEDU), 5-(3-chloropropyl)-2'-deoxyuridine (CPDU), and 5-(2-chloroethyl)-2'-deoxycytidine (CEDC) were evaluated for activity against herpes simplex virus type 1 (HSV-1) and HSV-2 in vitro. Their MICs for HSV-1 in primary rabbit kidney cell cultures were 0.15, 0.20, and 0.60 micrograms/ml, respectively; their MICs for HSV-2 were about 10-fold higher. When tested in parallel, the reference compounds 5-ethyl-2'-deoxyuridine, 5-iodo-2'-deoxyuridine, acyclovir, and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) gave MICs of 0.20, 0.18, 0.04, and 0.015 micrograms/ml, respectively. The antiviral indexes of CEDU, CPDU, and CEDC, as determined by the ratio of the minimum toxic dose for the normal host cell to the minimum inhibitory dose for HSV-1, were about 2,000, 100, and greater than or equal to 400, respectively. The three 5-(2-haloalkyl)pyrimidine derivatives were further evaluated for their antiviral effects in vivo. In hairless mice, CEDU suppressed the development of cutaneous HSV-1 lesions, and associated mortality, when applied topically at a concentration as low as 0.1%. For the treatment of systemic HSV-1 infection in Naval Medical Research Institute mice, a single oral dose per day of 5 mg of CEDU per kg achieved a significant reduction in the mortality rate. Against HSV-1 encephalitis, CEDU exerted a significant protective effect at a dosage of 50 mg/kg per day when administered intraperitoneally. CEDU was effective against systemic HSV-1 infection and HSV-1 encephalitis in mice at a 5- to 15-fold-lower dose than either BVDU or acyclovir. When given orally, CPDU and CEDC were considerably less active than CEDU against systemic HSV-1 infection.

Full text

PDF
246

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allaudeen H. S., Chen M. S., Lee J. J., De Clercq E., Prusoff W. H. Incorporation of E-5-(2-halovinyl)-2'-deoxyuridines into deoxyribonucleic acids of herpes simplex virus type 1-infected cells. J Biol Chem. 1982 Jan 25;257(2):603–606. [PubMed] [Google Scholar]
  2. Allaudeen H. S., Kozarich J. W., Bertino J. R., De Clercq E. On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine. Proc Natl Acad Sci U S A. 1981 May;78(5):2698–2702. doi: 10.1073/pnas.78.5.2698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ashton W. T., Karkas J. D., Field A. K., Tolman R. L. Activation by thymidine kinase and potent antiherpetic activity of 2'-nor-2'-deoxyguanosine (2'NDG). Biochem Biophys Res Commun. 1982 Oct 29;108(4):1716–1721. doi: 10.1016/s0006-291x(82)80109-5. [DOI] [PubMed] [Google Scholar]
  4. Balzarini J., De Clercq E., Ayusawa D., Seno T. Thymidylate synthetase-deficient mouse FM3A mammary carcinoma cell line as a tool for studying the thymidine salvage pathway and the incorporation of thymidine analogues into host cell DNA. Biochem J. 1984 Jan 1;217(1):245–252. doi: 10.1042/bj2170245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Balzarini J., De Clercq E., Torrence P. F., Mertes M. P., Park J. S., Schmidt C. L., Shugar D., Barr P. J., Jones A. S., Verhelst G. Role of thymidine kinase in the inhibitory activity of 5-substituted-2'-deoxyuridines on the growth of human and murine tumor cell lines. Biochem Pharmacol. 1982 Mar 15;31(6):1089–1095. doi: 10.1016/0006-2952(82)90347-1. [DOI] [PubMed] [Google Scholar]
  6. Benoit Y., Laureys G., Delbeke M. J., De Clercq E. Oral BVDU treatment of varicella and zoster in children with cancer. Eur J Pediatr. 1985 Jan;143(3):198–202. doi: 10.1007/BF00442138. [DOI] [PubMed] [Google Scholar]
  7. Bergstrom D. E., Ruth J. L., Reddy P. A., De Clercq E. Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1. J Med Chem. 1984 Mar;27(3):279–284. doi: 10.1021/jm00369a009. [DOI] [PubMed] [Google Scholar]
  8. Cheng Y. C., Dutschman G., De Clercq E., Jones A. S., Rahim S. G., Verhelst G., Walker R. T. Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins. Mol Pharmacol. 1981 Jul;20(1):230–233. [PubMed] [Google Scholar]
  9. De Clercq E., Balzarini J., Descamps J., Huang G. F., Torrence P. F., Bergstrom D. E., Jones A. S., Serafinowski P., Verhelst G., Walker R. T. Antiviral, antimetabolic, and cytotoxic activities of 5-substituted 2'-deoxycytidines. Mol Pharmacol. 1982 Jan;21(1):217–223. [PubMed] [Google Scholar]
  10. De Clercq E., Descamps J., Balzarini J., Fukui T., Allaudeen H. S. Antiviral activity of the 3'-amino derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine. Biochem J. 1983 May 1;211(2):439–445. doi: 10.1042/bj2110439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. De Clercq E., Descamps J., Huang G. F., Torrence P. F. 5-Nitro-2'-deoxyuridine and 5-nitro-2'-deoxyuridine 5'-monophosphate: antiviral activity and inhibition of thymidylate synthetase in vivo. Mol Pharmacol. 1978 May;14(3):422–430. [PubMed] [Google Scholar]
  12. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  13. Descamps J., De Clercq E. Specific phosphorylation of E-5-(2-iodovinyl)-2'-deoxyuridine by herpes simplex virus-infected cells. J Biol Chem. 1981 Jun 25;256(12):5973–5976. [PubMed] [Google Scholar]
  14. Desgranges C., Razaka G., Drouillet F., Bricaud H., Herdewijn P., De Clercq E. Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-deoxyuridine in vivo. Nucleic Acids Res. 1984 Feb 24;12(4):2081–2090. doi: 10.1093/nar/12.4.2081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Desgranges C., Razaka G., Rabaud M., Bricaud H., Balzarini J., De Clercq E. Phosphorolysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted-2'-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets. Biochem Pharmacol. 1983 Dec 1;32(23):3583–3590. doi: 10.1016/0006-2952(83)90307-6. [DOI] [PubMed] [Google Scholar]
  16. Field A. K., Davies M. E., DeWitt C., Perry H. C., Liou R., Germershausen J., Karkas J. D., Ashton W. T., Johnston D. B., Tolman R. L. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4139–4143. doi: 10.1073/pnas.80.13.4139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Machida H., Sakata S., Kuninaka A., Yoshino H. Antiherpesviral and anticellular effects of 1-beta-D-arabinofuranosyl-E-5-(2-halogenovinyl) uracils. Antimicrob Agents Chemother. 1981 Jul;20(1):47–52. doi: 10.1128/aac.20.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mancini W. R., De Clercq E., Prusoff W. H. The relationship between incorporation of E-5-(2-Bromovinyl)-2'-deoxyuridine into herpes simplex virus type 1 DNA with virus infectivity and DNA integrity. J Biol Chem. 1983 Jan 25;258(2):792–795. [PubMed] [Google Scholar]
  19. Maudgal P. C., De Clercq E., Missotten L. Efficacy of bromovinyldeoxyuridine in the treatment of herpes simplex virus and varicella-zoster virus eye infections. Antiviral Res. 1984 Oct;4(5):281–291. doi: 10.1016/0166-3542(84)90033-0. [DOI] [PubMed] [Google Scholar]
  20. Schaeffer H. J., Beauchamp L., de Miranda P., Elion G. B., Bauer D. J., Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature. 1978 Apr 13;272(5654):583–585. doi: 10.1038/272583a0. [DOI] [PubMed] [Google Scholar]
  21. Watanabe K. A., Reichman U., Hirota K., Lopez C., Fox J. J. Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides. J Med Chem. 1979 Jan;22(1):21–24. doi: 10.1021/jm00187a005. [DOI] [PubMed] [Google Scholar]
  22. Watanabe K. A., Su T. L., Reichman U., Greenberg N., Lopez C., Fox J. J. Nucleosides. 129. Synthesis of antiviral nucleosides: 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracils. J Med Chem. 1984 Jan;27(1):91–94. doi: 10.1021/jm00367a020. [DOI] [PubMed] [Google Scholar]
  23. Wildiers J., De Clercq E. Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine treatment of severe herpes zoster in cancer patients. Eur J Cancer Clin Oncol. 1984 Apr;20(4):471–476. doi: 10.1016/0277-5379(84)90231-1. [DOI] [PubMed] [Google Scholar]
  24. Young C. W., Schneider R., Leyland-Jones B., Armstrong D., Tan C. T., Lopez C., Watanabe K. A., Fox J. J., Philips F. S. Phase I evaluation of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in immunosuppressed patients with herpesvirus infection. Cancer Res. 1983 Oct;43(10):5006–5009. [PubMed] [Google Scholar]
  25. de Clercq E. Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds. Antimicrob Agents Chemother. 1984 Aug;26(2):155–159. doi: 10.1128/aac.26.2.155. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES